After 19 months, FDA lifts clinical hold on vaginal yeast infection drug Brexafemme

16th May 2025 Uncategorised 0

The FDA has lifted its 19-month clinical hold on vaginal yeast infection drug Brexafemme (ibrexafungerp), according to the treatment’s developer Scynexis.

More: After 19 months, FDA lifts clinical hold on vaginal yeast infection drug Brexafemme
Source: fierce